Literature DB >> 30996086

Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry.

Justyna Broniarczyk1,2, Paola Massimi1, David Pim1, Martina Bergant Marušič3, Michael P Myers4, Robert L Garcea5, Lawrence Banks6.   

Abstract

The human papillomavirus (HPV) capsid comprises two viral proteins, L1 and L2, with the L2 component being essential to ensure efficient endocytic transport of incoming viral genomes. Several studies have previously reported that L1 and L2 are posttranslationally modified, but it is uncertain whether these modifications affect HPV infectious entry. Using a proteomic screen, we identified a highly conserved phospho-acceptor site on the HPV-16 and bovine papillomavirus 1 (BPV-1) L2 proteins. The phospho-modification of L2 and its presence in HPV pseudovirions (PsVs) were confirmed using anti-phospho-L2-specific antibodies. Mutation of the phospho-acceptor sites of both HPV-16 and BPV-1 L2 resulted in the production of infectious virus particles, with no differences in efficiencies of packaging the reporter DNA. However, these mutated PsVs showed marked defects in infectious entry. Further analysis revealed a defect in uncoating, characterized by a delay in the exposure of a conformational epitope on L1 that indicates capsid uncoating. This uncoating defect was accompanied by a delay in the proteolysis of both L1 and L2 in mutated HPV-16 PsVs. Taken together, these studies indicate that phosphorylation of L2 during virus assembly plays an important role in optimal uncoating of virions during infection, suggesting that phosphorylation of the viral capsid proteins contributes to infectious entry.IMPORTANCE The papillomavirus L2 capsid protein plays an essential role in infectious entry, where it directs the successful trafficking of incoming viral genomes to the nucleus. However, nothing is known about how potential posttranslational modifications may affect different aspects of capsid assembly or infectious entry. In this study, we report the first phospho-specific modification of the BPV-1 and HPV-16 L2 capsid proteins. The phospho-acceptor site is very highly conserved across multiple papillomavirus types, indicating a highly conserved function within the L2 protein and the viral capsid. We show that this modification plays an essential role in infectious entry, where it modulates susceptibility of the incoming virus to capsid disassembly. These studies therefore define a completely new means of regulating the papillomavirus L2 proteins, a regulation that optimizes endocytic processing and subsequent completion of the infectious entry pathway.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  HPV; L2; infection; protein phosphorylation

Mesh:

Substances:

Year:  2019        PMID: 30996086      PMCID: PMC6580975          DOI: 10.1128/JVI.00128-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS.

Authors:  B L Allen-Hoffmann; S J Schlosser; C A Ivarie; C A Sattler; L F Meisner; S L O'Connor
Journal:  J Invest Dermatol       Date:  2000-03       Impact factor: 8.551

2.  A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes.

Authors:  David Fenyö; Ronald C Beavis
Journal:  Anal Chem       Date:  2003-02-15       Impact factor: 6.986

3.  Atomic model of the papillomavirus capsid.

Authors:  Yorgo Modis; Benes L Trus; Stephen C Harrison
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

4.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Human papillomavirus infection requires cell surface heparan sulfate.

Authors:  T Giroglou; L Florin; F Schäfer; R E Streeck; M Sapp
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 6.  Papillomaviruses and cancer: from basic studies to clinical application.

Authors:  Harald zur Hausen
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

7.  The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes.

Authors:  J G Joyce; J S Tung; C T Przysiecki; J C Cook; E D Lehman; J A Sands; K U Jansen; P M Keller
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

8.  Cell surface-binding motifs of L2 that facilitate papillomavirus infection.

Authors:  Rongcun Yang; Patricia M Day; William H Yutzy; Ken-Yu Lin; Chien-Fu Hung; Richard B S Roden
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.

Authors:  Patricia M Day; Carl C Baker; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

10.  Detection of arginine dimethylated peptides by parallel precursor ion scanning mass spectrometry in positive ion mode.

Authors:  Juri Rappsilber; Westley J Friesen; Sergey Paushkin; Gideon Dreyfuss; Matthias Mann
Journal:  Anal Chem       Date:  2003-07-01       Impact factor: 6.986

View more
  2 in total

Review 1.  New Perspectives in Therapeutic Vaccines for HPV: A Critical Review.

Authors:  Barbara Gardella; Andrea Gritti; Ehsan Soleymaninejadian; Marianna Francesca Pasquali; Gaetano Riemma; Marco La Verde; Maria Teresa Schettino; Nicola Fortunato; Marco Torella; Mattia Dominoni
Journal:  Medicina (Kaunas)       Date:  2022-06-28       Impact factor: 2.948

2.  Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis.

Authors:  Sarah Mole; Arwa Ali A Faizo; Hegel Hernandez-Lopez; Megan Griffiths; Andrew Stevenson; Sally Roberts; Sheila V Graham
Journal:  J Gen Virol       Date:  2020-03-13       Impact factor: 3.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.